Rare disease

Laboratory research
#Clinical trials #Genetic diseases #Rare disease #Washington University School of Medicine

New US centre for rare diseases to promote drug research

Washington University School of Medicine in St Louis has launched the Center for Rare, Undiagnosed and Genetic Diseases, supported by an $8.5 million grant from Children’s Discovery Institute (CDI), a partnership with St Louis Children’s Hospital, St Louis Children’s Hospital Foundation and WashU Medicine.   The new centre… Read More

#News

Monoclonal antibodies
#CSL #European Commission #Monoclonal antibodies #Rare disease

EC approves antibody to prevent hereditary angioedema attacks

The European Commission (EC) has approved Andembry (garadacimab), the only once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.  Andembry inhibits plasma protein factor XIIa, which initiates the cascade of events leading to angioedema at various sites… Read More

#News #Regulatory

#Clinical trials #CNS #Drug development #Drug discovery #Rare disease

The difficulties of rare disease clinical trials

Late-stage biotech Minoryx is developing a therapy (leriglitazone) targeting patients with the rare progressive CNS disease cerebral adrenoleukodystrophy (cALD). If approved, it would give patients another choice of treatment options outside of stem cell transplants and gene therapies. Data presented last year for leriglitazone showed it stopped cALD disease progression… Read More

#Exclusive Content

B-cells in multiple myeloma
#Cancer immunotherapy #FDA #MAIA Biotechnology #Paediatrics #Rare disease

Telomere-targeting agent granted Rare Pediatric Disease designation

The US Food and Drug Administration (FDA) has designated MAIA Biotechnology’s immunotherapy THIO for the treatment of paediatric-type diffuse high-grade gliomas (PDHGG) as a drug for a rare paediatric disease. “THIO is a versatile anti-cancer agent that has demonstrated positive results in multiple difficult to treat cancer types, including paediatric… Read More

#Cancer Research #News

Blood samples in lab
#blood #Clinical trial #Fc-Fusion proteins #Proteins #Rare disease #Thrombotic diseases

First patients dosed in thrombolytic drug trial

TargED Biopharmaceuticals, a biotechnology company focused on developing improved treatments for thrombotic diseases, has dosed the first participant with TGD001. TGD001 is a thrombolytic designed to break down clots of all sizes and compositions – from large clots which cause AIS, down to ‘micro-clots’ which cause conditions such as the… Read More

#News

Transfer RNA
#Alltrna #Flagship Pioneering #Mouse models #Oligonucleotides #Rare disease #RNA #tRNA

First tRNA development candidate restores protein production

Data demonstrate that engineered tRNA from Alltrna’s first development candidate restores protein production to clinically meaningful levels in two disease models driven by the same premature termination codon.  AP003 is a chemically modified, engineered tRNA oligonucleotide in a clinically validated, liver-directed lipid nanoparticle (LNP) that can readthrough… Read More

#News

#Applied Therapeutics #CNS #FDA #Genetic diseases #Rare disease

Patient groups urge FDA to reconsider govorestat rejection

The US Food and Drug Administration’s (FDA) decision not to approve govorestat, a central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI) for Classic Galactosemia, has been met with criticism from patient groups.  Govorestat is the only investigational treatment to be evaluated for Galactosemia, a rare genetic disease that can be… Read More

#News #Regulatory #Trending News

Gene therapy
#FDA #Gene therapy #Neurology #Neuroscience #PTC Therapeutics #Rare disease

FDA approves first gene therapy for rare genetic disorder

The US Food and Drug Administration (FDA) has approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy for the treatment of adult and paediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters,… Read More

#News #Regulatory

Stamp of approval
#AstraZeneca #European Commission #Phase III trial #Rare disease

EU approves new indication for AstraZeneca’s Fasenra

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated vasculitis that can result in damage to multiple organs, and without treatment, can be fatal. The approval by… Read More

#News #Regulatory

#Genetics / genomics #mRNA #Rare disease #RNA

How mRNA’s tiny cousin could treat thousands of rare diseases

DDW Editor Reece Armstrong speaks to Dr Caroline Kӧhrer, Vice President, Discovery Platform, Alltrna, about the biology behind tRNAs and how they could help produce a medicine that could treat thousands of rare diseases that share the same genetic mutation. RA: Why are tRNA molecules so important for rare genetic… Read More

#Exclusive Content

#Early access #Rare disease #Regulatory #Unlicensed drug

Bridging the gap between unlicensed medicines and unmet need

Suzanne Aitken, Senior Vice President of Managed Access at Clinigen, discusses the benefits of unlicensed medicines (ULMs) and why regulators and the industry need to do more to improve patient access to these therapies.  The pharmaceutical industry is constantly changing. However, an unwavering problem is the constant unmet need facing… Read More

#Exclusive Content #Opinion

Human liver
#European Commission #Ipsen #Liver disease #Phase III trial #Rare disease

EU approves first new treatment for rare liver disease in a decade

The European Commission has conditionally approved Iqirvo (elafibranor) 80mg tablets for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA). The approval is limited to adults with an inadequate response to UDCA or as a monotherapy in patients unable to tolerate UDCA. Iqirvo is a first-in-class,… Read More

#News #Regulatory

#Cystic fibrosis #Financing #Funding #Neuroscience #Oncology #Rare disease

This week in drug discovery (30 Sept – 4 Oct) 

News round-up for 30 Sept – 4 Oct by DDW Senior Digital Content Editor Diana Spencer. The theme of the news highlights this week is funding, with companies raising considerable levels of private investment, alongside new funding grants to advance the development of therapeutics for lung infections in… Read More

#News

Laboratory research
#Clinical trials #FDA #Funding #Orphan drugs #Rare disease

FDA awards grants to seven clinical trials for orphan products

The US Food and Drug Administration (FDA) has announced seven new clinical trial grants awarded under the Orphan Products Grants Program for clinical trials to address the unmet needs of people affected by rare diseases. In total, clinical researchers will receive approximately $17.2 million over the next four years. Newly… Read More

#News #Regulatory

Saline intravenous (iv) drip in a child's hand
#Cystic fibrosis #FDA #Paediatrics #Rare disease

Three drugs secure ‘rare paediatric disease designation’ in the US

Three drugs have been granted ‘rare paediatric disease designation’ (RPDD) in the US by the Food and Drug Administration (FDA). The FDA grants RPDD for serious or life-threatening diseases that affect fewer than 200,000 people in the United States and primarily affect patients less than 18 years of age. ETD001… Read More

#News #Regulatory

The European Medicines Agency in Amsterdam
#AstraZeneca #CHMP #European Medicines Agency #Rare disease

EU CHMP recommends new indication for AZ’s benralizumab

AstraZeneca’s Fasenra (benralizumab) has been recommended for approval in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated vasculitis that can result in damage to multiple organs, and without treatment, can be fatal. If… Read More

#News #Regulatory